Inflammatory disease Archives

News and Trends 6 Jun 2020

Boost For Inflammatory Disease Biotech NodThera With €49M Series B

The UK-US biotech NodThera has raised €48.7M in Series B funding to progress its drug candidate through clinical trials for the treatment of inflammatory conditions such as inflammatory bowel disease. This round follows an impressive €32M Series A that Nodthera carried out in 2018. Danish firm Novo Ventures, part of the investment arm of Novo […]

June 6, 2020 - 3 minutesmins - By Helen Albert

lupus autoimmune disease neutrophil citryll

More News! 26 Nov 2019

Rare Inflammatory Disease Drug Beats Immunosuppressants in Phase III

A small molecule drug developed by the US company ChemoCentryx and its Swiss partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP) was more effective at treating a rare inflammatory vascular disease than current treatments in a phase III trial. The drug avacopan was trialed in 331 patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. This life-threatening condition […]

November 26, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 21 Oct 2019

Update: Abivax’s Ulcerative Colitis Drug Effective Long-Term

Update (21/10/2019): An extension of French biotech Abivax’s phase IIa trial shows its treatment for the inflammatory bowel disease ulcerative colitis has good efficacy after a year of treatment, with 75% of the screened patients remaining symptom-free. Of the 32 patients in the original phase IIa trial, 19 patients were treated with Abivax’s drug in […]

October 21, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 12 Sep 2019

French Biotech to Develop Septic Shock Therapy with €39M Series B

The French company Inotrem has raised €39M to fund an immunotherapy for septic shock, an often deadly condition caused by infections in the bloodstream. Led by the Hong Kong investor Morningside Ventures, the Series B round will finance a phase IIb trial of Inotrem’s lead candidate drug nangibotide, expected to start in November this year. […]

September 12, 2019 - 3 minutesmins - By Jonathan Smith

Ose Immunotherapeutics bpifrance milestone bowel disease

News and Trends 27 Aug 2019

Swedish Ulcerative Colitis Treatment Makes Phase II Comeback

InDex Pharmaceuticals’ ulcerative colitis drug candidate has achieved positive phase IIb results, suggesting work to improve its dosage after a previous phase III failure was successful. The Swedish company tested different doses of the small molecule drug cobitolimod against a placebo in patients with the inflammatory bowel disease ulcerative colitis. The 213 patients in the […]

August 27, 2019 - 2 minutesmins - By Jonathan Smith

acute respiratory distress syndrome pantherna berlin inflammatory disease

Startup Scout 2 Aug 2019

This Biotech Uses Messenger RNA to Treat Lethal Lung Inflammation

Based close to Berlin, Germany, the biotech startup Pantherna Therapeutics is developing a messenger RNA drug to treat a life-threatening lung condition that requires mechanical ventilation. Mission: To develop a messenger RNA (mRNA) drug to treat acute respiratory distress syndrome, an inflammatory lung reaction that kills up to half of patients with the condition. Acute […]

August 2, 2019 - 4 minutesmins - By Jonathan Smith

atlantic healthcare pouchitis inflammatory bowel disease

More News! 1 Aug 2019

Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III

Hopes of seeing an approved treatment for the inflammatory bowel condition pouchitis have been dashed as the UK company Atlantic Healthcare’s RNA drug has proved ineffective in a phase III trial. The trial tested Atlantic Healthcare’s RNA drug alicaforsen as a treatment for patients with pouchitis. Patients with this condition have their colon surgically replaced […]

August 1, 2019 - 2 minutesmins - By Jonathan Smith

inflammatory bowel disease treatment personalized medicine predictimmune

News and Trends 31 Jul 2019

British Biotech Raises €11M to Market Personalized Medicine Test

The UK biotech PredictImmune has raised €11M (£10M) in a Series B fundraising round to commercialize technology to predict the progress of inflammatory bowel disease in newly diagnosed patients. The funds will finance the global launch of PredictSURE IBD, a blood test that can identify patients with the most severe cases of inflammatory bowel disease, […]

July 31, 2019 - 3 minutesmins - By Jonathan Smith

More News! 25 Jul 2019

German Biotech Breath Therapeutics Acquired in Deal Worth up to €500M

The Italian company Zambon has acquired the German biotech Breath Therapeutics for up to €500M, getting hold of its treatment for a rare lung disease known as popcorn lung. The deal includes an upfront payment of €140M and up to €360M upon reaching undisclosed regulatory milestones. Zambon will take over the development of a treatment […]

July 25, 2019 - 2 minutesmins - By Jonathan Smith

gilead galapagos arthritis pulmonary fibrosis

News and Trends 15 Jul 2019

Gilead Pays Billions for Access to Galapagos’ Pipeline

Gilead has launched a 10-year collaboration with the Belgo-Dutch biotech Galapagos, paying at least €4.5B ($5.1B) for commercial rights to Galapagos’s whole pipeline, including a phase III drug for pulmonary fibrosis. As part of the deal, Gilead will pay Galapagos €3.5B ($3.95B) upfront, with a further €1B ($1.1B) in equity investment. In return, Gilead gets […]

July 15, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 4 Jul 2019

Dutch Antibodies for Autoimmune Diseases Boosted by €15M Series A

The Dutch biotech Citryll has raised €15M to develop antibodies that could fight autoimmune and inflammatory diseases more effectively than current treatments by inhibiting the innate immune system. The Series A funds will be used to launch the clinical development of Citryll’s lead antibody, which is designed to treat the autoimmune condition lupus. The money […]

July 4, 2019 - 2 minutesmins - By Jonathan Smith

inflarx trial inflammatory disease fail skin

More News! 6 Jun 2019

Shares Drop 90% as Antibody for Inflammatory Skin Disease Fails Phase II

The German company InflaRx has seen its shares on the Nasdaq plummet after announcing that its treatment for an inflammatory skin disease failed to beat the placebo in a phase IIb trial. The trial had enrolled 179 patients with hidradenitis suppurativa, an incurable condition causing painful lumps on the skin. By the 16th week of […]

June 6, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Inflammatory disease

Boost For Inflammatory Disease Biotech NodThera With €49M Series B

Rare Inflammatory Disease Drug Beats Immunosuppressants in Phase III

Update: Abivax’s Ulcerative Colitis Drug Effective Long-Term

French Biotech to Develop Septic Shock Therapy with €39M Series B

Swedish Ulcerative Colitis Treatment Makes Phase II Comeback

This Biotech Uses Messenger RNA to Treat Lethal Lung Inflammation

Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III

British Biotech Raises €11M to Market Personalized Medicine Test

German Biotech Breath Therapeutics Acquired in Deal Worth up to €500M

Gilead Pays Billions for Access to Galapagos’ Pipeline

Dutch Antibodies for Autoimmune Diseases Boosted by €15M Series A

Shares Drop 90% as Antibody for Inflammatory Skin Disease Fails Phase II

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!